{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:48Z","timestamp":1787841048533,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapy-related acute myeloid leukemia (tAML) is a serious complication in patients with Non-Hodgkin lymphoma (NHL) exposed to chemotherapy or radiation. This extensive database study aims to quantify the risk of tAML in NHL and determine the impact of tAML on the overall survival (OS) of patients with NHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>Patients diagnosed with NHL and de novo AML from 2009 to 2018 were identified from the Surveillance, Epidemiology, and End Results database. Multiple primary standardized incidence ratio (SIR) sessions of the SEER*Stat software were used to calculate SIR and the absolute excess risk of tAML. Overall survival (OS) was evaluated using Kaplan\u2013Meier curves and compared using log-rank tests. Multivariate analysis was used to study the role of each covariate on OS in patients with tAML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The SIR of tAML was 4.89 (95% CI 4.41\u20135.41), with a higher incidence of tAML observed for age &lt;60 years, NHL prior to 2013 and within 5 years of diagnosis, and those who received chemotherapy. NHL patients with tAML had lower OS than those without tAML (5-year OS 59% vs. 13%, p &lt; 0.001). Patients with tAML showed worse OS than de novo AML in univariate analysis (5-year OS 13% vs. 25%, p = 0.001) but not in multivariate analysis (HR 0.93, 95% CI 0.82\u20131.04, p = 0.21). Age &gt;60 years and lack of chemotherapy were associated with poor OS in tAML subcategory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Age, time since NHL diagnosis, and receipt of chemotherapy directly influence the risk of development of tAML in NHL survivors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.56875\/2589-0646.1113","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T09:05:16Z","timestamp":1691571916000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Therapy-related Acute Myeloid Leukemia in Non-Hodgkin Lymphoma Survivors: Risk, Survival Outcomes and Prognostic Factor Analysis"],"prefix":"10.4103","volume":"17","author":[{"given":"Utsav","family":"Joshi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adheesh","family":"Bhattarai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Gaire","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mount Sinai Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravash","family":"Budhathoki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Bronx Care Health System, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishakha","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Subedi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Unity Hospital, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishesh S.","family":"Poudyal","sequence":"additional","affiliation":[{"name":"Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sham","sequence":"additional","affiliation":[{"name":"Division of Hematology and Clinical Oncology, Rochester General Hospital, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya R.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA"},{"name":"Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"15","key":"R1-20241211","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"9","key":"R2-20241211","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"R3-20241211","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of Chemotherapy for Solid Tumors with Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"R4-20241211","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"23","key":"R5-20241211","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jnci\/85.23.1932","article-title":"Second cancers among long-term survivors of non-Hodgkin\u2019s lymphoma","volume":"85","author":"Travis","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"R6-20241211","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.12684","article-title":"Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden","volume":"164","author":"Lorenzo","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"R7-20241211","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"13","key":"R8-20241211","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2217\/fon-2016-0048","article-title":"Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma","volume":"12","author":"Bhatt","year":"2016","journal-title":"Future Oncol"},{"issue":"3","key":"R9-20241211","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol"},{"key":"R10-20241211","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2022.01.001","article-title":"Impact of insurance on overall survival in acute lymphoblastic leukemia: a SEER database study","author":"Joshi","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"R11-20241211","first-page":"1481","article-title":"Risk of second cancer after treatment of aggressive non-Hodgkin\u2019 s lymphoma; an EORTC cohort study","volume":"91","author":"Moser","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"R12-20241211","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"issue":"31","key":"R13-20241211","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study","volume":"33","author":"\u00d8stg\u00e2rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"R14-20241211","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.2004.99.301","article-title":"Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype","volume":"22","author":"Kern","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"R16-20241211","first-page":"2015","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study","volume":"101","author":"Metayer","year":"2003","journal-title":"Blood J Am Soc Hematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:41:12Z","timestamp":1787838072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.56875\/2589-0646.1113","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"2022-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}